Introduction: Cervical cancer remains a leading cause of cancer-related morbidity and mortality worldwide, underscoring the urgent need for robust biomarkers to improve diagnosis, prognosis, and therapeutic decision-making. Objectives: To identify and prioritize a panel of potential biomarkers and biological pathways in cervical cancer tissue samples including Tumor (TU), Peritumor (PTT), and Non-Cancer (NC) regions. Methods: The institutional ethics committee approved the study under the protocol number CAAE: 79292824.0.0000.5634. The samples were sequenced on an Illumina NextSeq 500 platform using mRNA-seq. RNA-seq data processing was performed using the nf-core/rnaseq v3.1.4 pipeline. Differential gene expression analysis (DESeq2 package in R, adjusted p-value < 0.05 and abs(log2FoldChange) > 1), ROC curve (AUC ? 0.9), and clinical annotation via the OncoKB database were integrated to identify and prioritize clinically relevant biomarkers. Additionally, the parameter ‘baseMean’ was used to apply an additional filtering step where genes falling at or above the first quartile of the ‘BaseMean’ distribution for each condition’s median were included. Minimum ‘BaseMean’ values for TU-PTT, TU-NC, and PTT-NC conditions were 4.48, 8.59, and 7.13 respectively. Functional enrichment analyses using Gene Ontology and KEGG pathways (FDR < 0.05) were performed to elucidate biological processes and pathways associated with these biomarkers. Results: A panel of 40 potential biomarkers were identified and categorized as 18 oncogenes, 21 tumor suppressor genes, and 9 actionable genes. Biomarkers were unique to TU-PTT and TU-NC comparisons, with no candidates identified in PTT-NC. Distinct pathways were enriched by unique biomarkers in each condition: cysteine and methionine metabolism, TGF-beta signaling, and viral infection pathways (TU-PTT); and pancreatic cancer, breast cancer, melanoma, and central carbon metabolism pathways (TU-NC). Common biomarkers between TU-PTT and TU-NC, FANCA and BRCA1, were associated with key DNA repair-related pathways, including Fanconi anemia (FA), homologous recombination (HR), and platinum drug resistance. Genes within the FA and HR pathways, such as BRIP1, RAD51C, XRCC2, and RAD54L, were consistently overexpressed, indicating dysregulated DNA repair mechanisms in cervical tumors. Conclusion: Our study identified a panel of clinically relevant biomarkers and molecular signatures distinguishing tumor and non-cancerous cervical tissues (PTT, and NC). Key DNA repair-associated genes, emerged as promising candidates for diagnostic, prognostic, and therapeutic applications in cervical cancer. These findings provide a foundation for biomarker-driven strategies to improve clinical management, warranting validation in larger patient cohorts.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
